Pharmaceutical

Signal: Danaher’s $5.7bn acquisition of Abcam faces stand-off with founder

Abcam founder Jonathan Milner has declared his intention to vote against the acquisition of the company in which he holds a large stake.

Sep 15, 2023 - 20:00
Signal: Danaher’s $5.7bn acquisition of Abcam faces stand-off with founder
Abcam founder Jonathan Milner has declared his intention to vote against the acquisition of the company in which he holds a large stake.
Read the original article

Tags:

Previous Article

argenx wins EMA CHMP nod for subcutaneous Vyvgart in myasthenia gravis

Next Article

Cure Genetics and Frametact seek gene cures for neurological ailments

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Sosei to regain rights to IBD drug after GSK discontinues programme

Sosei to regain rights to IBD drug after GSK discontinu...

Nov 24, 2023

STAT+: FDA’s Woodcock, other experts highlight persistent issues plaguing pharma, biotech in the wake of Covid-19

STAT+: FDA’s Woodcock, other experts highlight persiste...

Nov 7, 2023

Opinion: Pumping milk at JPM was a nightmare. It’s part of a bigger problem in the industry

Opinion: Pumping milk at JPM was a nightmare. It’s part...

Jan 12, 2024